Scientists track Melanoma's metabolic tricks in tiny study

NCT ID NCT04658303

Recruiting now Knowledge-focused Sponsor: Yana Najjar Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at melanoma tumors that spread between the main tumor and nearby lymph nodes (called in-transit metastases). Researchers will take biopsies from different spots and use a safe tracer to measure oxygen levels. They aim to understand how these tumors change metabolically and immunologically as they move away from the original site. The study involves 20 adults with melanoma and does not test any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pimonidazole (a chemical tracer to detect low oxygen in tumors)
What this could lead to: If successful, this could help doctors understand why some melanoma spots resist treatment, potentially guiding better combination therapies.
What could go wrong: This is a very small, early observational study (20 people) with no treatment being tested. It aims to gather knowledge, not to cure or treat disease directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

immune system disorder melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.